###begin article-title 0
Activin-A induces regulatory T cells that suppress T helper cell immune responses and protect from allergic airway disease
###end article-title 0
###begin p 1
T. Alissafi and M. Aggelakopoulou contributed equally to this paper.
###end p 1
###begin p 2
V. Panoutsakopoulou and G. Xanthou contributed equally to this paper.
###end p 2
###begin p 3
###xml 413 417 <span type="species:ncbi:10090">mice</span>
Activin-A is a pleiotropic cytokine that participates in developmental, inflammatory, and tissue repair processes. Still, its effects on T helper (Th) cell-mediated immunity, critical for allergic and autoimmune diseases, are elusive. We provide evidence that endogenously produced activin-A suppresses antigen-specific Th2 responses and protects against airway hyperresponsiveness and allergic airway disease in mice. Importantly, we reveal that activin-A exerts suppressive function through induction of antigen-specific regulatory T cells that suppress Th2 responses in vitro and upon transfer in vivo. In fact, activin-A also suppresses Th1-driven responses, pointing to a broader immunoregulatory function. Blockade of interleukin 10 and transforming growth factor beta1 reverses activin-A-induced suppression. Remarkably, transfer of activin-A-induced antigen-specific regulatory T cells confers protection against allergic airway disease. This beneficial effect is associated with dramatically decreased maturation of draining lymph node dendritic cells. Therapeutic administration of recombinant activin-A during pulmonary allergen challenge suppresses Th2 responses and protects from allergic disease. Finally, we demonstrate that immune cells infiltrating the lungs from individuals with active allergic asthma, and thus nonregulated inflammatory response, exhibit significantly decreased expression of activin-A's responsive elements. Our results uncover activin-A as a novel suppressive factor for Th immunity and a critical controller of allergic airway disease.
###end p 3
###begin p 4
###xml 208 220 208 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib46">Reiner, 2007</xref>
###xml 222 236 222 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib59">Steinman, 2007</xref>
###xml 485 506 482 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">Nakamura et al., 2001</xref>
###xml 555 575 552 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">Asseman et al., 1999</xref>
###xml 577 594 574 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">Chen et al., 2003</xref>
###xml 596 625 593 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">Hawrylowicz and O'Garra, 2005</xref>
###xml 627 651 624 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib42">Ostroukhova et al., 2006</xref>
###xml 653 668 650 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">Li et al., 2007</xref>
###xml 755 772 752 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib64">von Boehmer, 2005</xref>
###xml 774 798 771 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib60">Tang and Bluestone, 2008</xref>
###xml 800 820 797 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib63">Vignali et al., 2008</xref>
Immune responses by differentiated effector Th1, Th2, and Th17 cell subsets provide protection against pathogens but can also lead to chronic inflammation, autoimmunity, or allergy if not tightly controlled (Reiner, 2007; Steinman, 2007). Critical controllers of these responses are immunosuppressive cytokines, such as IL-10 and TGF-beta1, and regulatory T lymphocytes. Subsets of regulatory T cells suppress responses by other effector Th cells mainly via cell-to-cell interactions (Nakamura et al., 2001) or the release of immunosuppressive cytokines (Asseman et al., 1999; Chen et al., 2003; Hawrylowicz and O'Garra, 2005; Ostroukhova et al., 2006; Li et al., 2007). However, blockade of these cytokines does not completely inhibit immune regulation (von Boehmer, 2005; Tang and Bluestone, 2008; Vignali et al., 2008), suggesting that other, as yet unidentified, cytokines are also involved.
###end p 4
###begin p 5
###xml 174 191 171 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib61">Vale et al., 1988</xref>
###xml 193 219 190 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib67">Werner and Alzheimer, 2006</xref>
###xml 231 234 228 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 222 234 219 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Activin-A<sup>&#8722;/&#8722;</sup></italic>
###xml 262 282 259 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">Matzuk et al., 1995b</xref>
###xml 293 318 290 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">activin receptor type IIA</italic>
###xml 320 328 317 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">act-RIIA</italic>
###xml 329 332 326 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 413 433 410 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">Matzuk et al., 1995a</xref>
###xml 656 672 653 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib43">Ota et al., 2003</xref>
###xml 706 725 703 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">Hubner et al., 1997</xref>
###xml 727 744 724 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">Dohi et al., 2005</xref>
###xml 824 850 821 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">Karagiannidis et al., 2006</xref>
###xml 924 946 921 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib52">Rosendahl et al., 2001</xref>
###xml 948 966 945 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Hardy et al., 2006</xref>
###xml 1025 1040 1022 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">Le et al., 2007</xref>
###xml 1087 1113 1084 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">Karagiannidis et al., 2006</xref>
###xml 1151 1169 1148 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">Ogawa et al., 2006</xref>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
###xml 333 337 <span type="species:ncbi:10090">mice</span>
###xml 905 909 <span type="species:ncbi:10090">mice</span>
###xml 1080 1085 <span type="species:ncbi:9606">human</span>
###xml 1119 1124 <span type="species:ncbi:10090">mouse</span>
The cytokine activin-A, a member of the TGF-beta superfamily, participates in essential biological processes, such as development, hematopoiesis, wound repair, and fibrosis (Vale et al., 1988; Werner and Alzheimer, 2006). Activin-A-/- mice are embryonic lethal (Matzuk et al., 1995b), whereas activin receptor type IIA (act-RIIA)-/- mice reach adulthood but have major deficiencies in their reproductive systems (Matzuk et al., 1995a). Although most studies have focused on the role of activin-A in developmental and fibrotic processes, certain reports demonstrate elevated levels of this cytokine in immune-mediated diseases such as rheumatoid arthritis (Ota et al., 2003) and inflammatory bowel disease (Hubner et al., 1997; Dohi et al., 2005). Activin-A is also increased in the sera of individuals with allergic asthma (Karagiannidis et al., 2006), and in the lung and bronchoalveolar lavage (BAL) of mice during acute (Rosendahl et al., 2001; Hardy et al., 2006) and chronic allergic airway inflammation and remodeling (Le et al., 2007). In addition, activin-A is induced in human (Karagiannidis et al., 2006) and mouse effector Th2 lymphocytes (Ogawa et al., 2006), which are key players in allergic responses. However, whether activin-A has enhancing or suppressive actions during Th immune responses and subsequent disease remains unclear.
###end p 5
###begin p 6
###xml 122 148 122 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">Karagiannidis et al., 2006</xref>
###xml 169 184 169 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib73">Yu et al., 1998</xref>
###xml 186 212 186 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib67">Werner and Alzheimer, 2006</xref>
###xml 277 296 277 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib48">Robson et al., 2009</xref>
###xml 417 434 417 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib66">Wang et al., 2008</xref>
###xml 436 453 436 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib72">Zhou et al., 2009</xref>
###xml 540 559 540 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib49">Robson et al., 2008</xref>
###xml 727 745 727 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Hardy et al., 2006</xref>
###xml 747 765 747 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">Jones et al., 2007</xref>
###xml 891 912 891 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib62">Veldhoen et al., 2006</xref>
###xml 914 935 914 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib74">Zenewicz et al., 2008</xref>
###xml 1057 1077 1057 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib70">Xanthou et al., 2007</xref>
###xml 112 117 <span type="species:ncbi:9606">human</span>
###xml 154 159 <span type="species:ncbi:10090">mouse</span>
###xml 249 254 <span type="species:ncbi:9606">human</span>
###xml 398 403 <span type="species:ncbi:10090">mouse</span>
###xml 515 520 <span type="species:ncbi:9606">human</span>
###xml 721 725 <span type="species:ncbi:10090">mice</span>
Certain studies indicate that recombinant activin-A (r-activin-A) reduces in vitro nonspecific proliferation of human Th (Karagiannidis et al., 2006) and mouse B cells (Yu et al., 1998; Werner and Alzheimer, 2006), and inhibits certain functions of human natural killer cells (Robson et al., 2009). In other reports, r-activin-A attenuates in vitro endotoxin-induced maturation and phagocytosis of mouse macrophages (Wang et al., 2008; Zhou et al., 2009) and CD40 ligand-dependent cytokine and chemokine release by human monocytes and DCs (Robson et al., 2008). Nevertheless, a few reports have suggested that activin-A has proinflammatory effects, i.e., during in vivo endotoxin administration and allergen challenge in mice (Hardy et al., 2006; Jones et al., 2007). Collectively, these studies indicate a dual nature of this cytokine, a characteristic feature of certain immune mediators (Veldhoen et al., 2006; Zenewicz et al., 2008). Of note, our previous studies revealed a dual role for another cytokine, osteopontin, in allergic airway inflammation (Xanthou et al., 2007).
###end p 6
###begin p 7
In the present study, we have investigated the in vivo role of activin-A in Th-mediated immune responses and, more specifically, during Th2-associated allergic airway inflammation. We demonstrate that antibody-mediated depletion of activin-A during pulmonary allergen challenge resulted in significant exacerbation of Th2-mediated allergic airway disease, indicating that endogenous activin-A is suppressive. In fact, our findings reveal that activin-A induces the generation of antigen-specific regulatory T cells that suppress both primary and effector Th responses in vitro and upon adoptive transfer in vivo. Functional in vitro analysis shows that activin-A-mediated suppressive effects on Th responses are dependent on both IL-10 and TGF-beta1. Importantly, activin-A-induced antigen-specific regulatory T cells transfer protection against allergic airway disease correlated with decreased DC maturation. Collectively, our data reveal that activin-A can suppress Th responses and represents a critical therapeutic target for allergic asthma.
###end p 7
###begin title 8
RESULTS
###end title 8
###begin title 9
Depletion of activin-A during allergen challenge in the airways enhances Th2 allergic responses and exacerbates asthmatic disease
###end title 9
###begin p 10
###xml 217 239 217 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib52">Rosendahl et al., 2001</xref>
###xml 241 259 241 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Hardy et al., 2006</xref>
###xml 261 287 261 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">Karagiannidis et al., 2006</xref>
###xml 502 510 502 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 461 465 <span type="species:ncbi:10090">mice</span>
We initially investigated the in vivo role of activin-A in Th-mediated responses and, more specifically, in Th2-associated allergic airway inflammation, as activin-A is expressed during Th2-driven allergic responses (Rosendahl et al., 2001; Hardy et al., 2006; Karagiannidis et al., 2006). For this, we administered a neutralizing antibody to activin-A (or Ig control) right before pulmonary allergen (OVA) challenge of OVA/aluminum hydroxide (alum)-sensitized mice (experimental protocol described in Fig. 1 A).
###end p 10
###begin p 11
###xml 0 121 0 121 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo depletion of activin-A during pulmonary allergen challenge exacerbates allergic airway disease and Th2 responses.</bold>
###xml 344 345 342 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 461 462 459 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 577 578 573 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 747 748 743 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1055 1056 1051 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1211 1212 1203 1204 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1295 1296 1285 1286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1548 1549 1532 1533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1740 1741 1722 1723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1926 1927 1906 1907 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2065 2066 2045 2046 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2069 2070 2049 2050 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2107 2114 2087 2094 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 2203 2204 2181 2182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 238 242 <span type="species:ncbi:10090">mice</span>
###xml 352 356 <span type="species:ncbi:10090">mice</span>
###xml 585 589 <span type="species:ncbi:10090">mice</span>
###xml 1063 1067 <span type="species:ncbi:10090">mice</span>
###xml 1303 1307 <span type="species:ncbi:10090">mice</span>
###xml 1556 1560 <span type="species:ncbi:10090">mice</span>
###xml 1707 1711 <span type="species:ncbi:10090">mice</span>
###xml 1748 1752 <span type="species:ncbi:10090">mice</span>
###xml 1934 1938 <span type="species:ncbi:10090">mice</span>
###xml 2029 2033 <span type="species:ncbi:10090">mice</span>
###xml 2211 2215 <span type="species:ncbi:10090">mice</span>
In vivo depletion of activin-A during pulmonary allergen challenge exacerbates allergic airway disease and Th2 responses. (A) Experimental protocol used to block endogenous activin-A during pulmonary challenge. (B) BAL differentials from mice treated with anti-activin-A or Ig control, or from the alum controls are expressed as means +/- SEM (n = 5-8 mice per group in four separate experiments). Statistical significance was obtained by an unpaired Student's t test (*, P = 0.0345; **, P = 0.0476). (C) AHR is depicted. Results shown for PenH are expressed as means +/- SEM (n = 5-8 mice per group in four separate experiments). Data were analyzed by two-way analysis of variance (ANOVA) for repeated measures, followed by an unpaired Student's t test (*, P = 0.0164; **, P = 0.00047). (D) Representative photomicrographs demonstrating lung inflammation (H&E-stained sections) and mucus secretion (PAS-stained sections). Histological scores of H&E-stained (***, P = 0.0009) and PAS-stained (***, P < 0.0001) sections. Error bars depict means of groups (n = 5-8 mice per group in four independent experiments). Bars, 100 microm. (E) DLN cells were restimulated ex vivo with OVA. Proliferation was measured by [3H]thymidine incorporation. Results are shown as means +/- SEM of triplicate wells (n = 5-8 mice per group in four independent experiments; ***, P < 0.0001). IL-4 (***, P < 0.0001), IL-13 (***, P < 0.0001), IL-10 (***, P < 0.0001), and IFN-gamma (***, P < 0.0001) in supernatants are shown. Results are means +/- SEM of duplicate wells (n = 5-8 mice per group in four independent experiments). (F) OVA-specific IgE (**, P = 0.0060), IgG1 (*, P = 0.0165), and IgG2a (*, P = 0.0218) in the sera of mice. Results are means +/- SEM (n = 5-8 mice per group in four independent experiments). (G) CCL11 (**, P = 0.0054), CCL17 (P = 0.9399), and CCL22 (P = 0.5000) in lung homogenates are shown. Results are means +/- SEM (n = 5-8 mice per group in four separate experiments). (H) DLN cells from anti-activin-A- or Ig-treated mice were co-cultured with LN KJ1-26+CD4+ T cells (2:1) in the presence of OVA323-339 peptide, and proliferation was measured (**, P = 0.001). The results are means +/- SEM (n = 5-8 mice per group in two independent experiments). Eos, eosinophils; LMs, lymphomononuclears; Macs, macrophages; Neuts, neutrophils.
###end p 11
###begin p 12
###xml 262 282 262 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">Humbles et al., 2004</xref>
###xml 284 300 284 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">Lee et al., 2004</xref>
###xml 334 342 334 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 561 569 561 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 C</xref>
###xml 697 705 697 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 C</xref>
###xml 827 835 827 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 D</xref>
###xml 1047 1055 1047 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 G</xref>
###xml 527 531 <span type="species:ncbi:10090">mice</span>
###xml 611 615 <span type="species:ncbi:10090">mice</span>
###xml 793 797 <span type="species:ncbi:10090">mice</span>
Depletion of activin-A during pulmonary allergen challenge resulted in significant exacerbation of allergic airway disease. This was shown by significantly increased total numbers of BAL-infiltrating cells and eosinophils, a hallmark of allergic airway disease (Humbles et al., 2004; Lee et al., 2004), as compared with Ig treatment (Fig. 1 B). More importantly, airway hyperresponsiveness (AHR) to increasing doses of inhaled methacholine, a clinical measurement of the asthmatic phenotype, was also significantly worsened in mice treated with anti-activin-A (Fig. 1 C). PBS/alum-sensitized and OVA-challenged mice (alum controls) exhibited lower AHR responses in comparison to the other groups (Fig. 1 C). Moreover, pulmonary inflammation and mucus secretion were significantly increased in mice treated with anti-activin-A (Fig. 1 D). The increase in eosinophilic infiltration, observed upon activin-A depletion at challenge, was accompanied by significantly increased expression of the eosinophil-specific chemokine CCL11 in lung homogenates (Fig. 1 G).
###end p 12
###begin p 13
###xml 514 522 514 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 E</xref>
###xml 660 668 656 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 E</xref>
###xml 905 924 901 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib65">Walter et al., 2001</xref>
###xml 926 956 922 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib56">Schnyder-Candrian et al., 2006</xref>
###xml 1099 1107 1095 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 F</xref>
###xml 1174 1182 1170 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 F</xref>
###xml 450 454 <span type="species:ncbi:10090">mice</span>
###xml 899 903 <span type="species:ncbi:10090">mice</span>
We also examined the effects of in vivo neutralization of activin-A on OVA-specific Th2-mediated effector responses by measuring Th cell proliferation and cytokine release in the supernatants of draining LN (DLN) cell cultures stimulated ex vivo with OVA. There was significantly increased OVA-specific Th cell proliferation and significantly increased production of the Th2 cytokines IL-4, IL-13, and IL-10 in stimulation cultures of DLN cells from mice treated with anti-activin-A, as compared with Ig controls (Fig. 1 E). IFN-gamma levels in culture supernatants were also significantly increased, possibly resulting from the overall enhanced inflammation (Fig. 1 E). In support, we observed significantly increased lung and BAL levels of IL-4, IL-13, and IL-10 concomitant with decreased production of IL-12 and IL-17, cytokines considered protective when overexpressed in the lungs of allergic mice (Walter et al., 2001; Schnyder-Candrian et al., 2006) upon activin-A depletion in vivo (not depicted). OVA-specific IgE and IgG1 (Th2 isotypes) serum concentrations were significantly increased (Fig. 1 F), whereas OVA-specific IgG2a (Th1 isotype) levels were decreased (Fig. 1 F).
###end p 13
###begin p 14
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 87 88 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 91 92 91 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 316 324 316 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 G</xref>
###xml 871 872 871 872 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 884 891 884 891 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 1007 1008 1007 1008 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1011 1012 1011 1012 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1036 1043 1036 1043 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 1053 1061 1053 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 H</xref>
###xml 163 167 <span type="species:ncbi:10090">mice</span>
###xml 643 647 <span type="species:ncbi:10090">mice</span>
###xml 755 759 <span type="species:ncbi:10090">mice</span>
###xml 947 951 <span type="species:ncbi:10090">mice</span>
No differences were observed in the recruitment of effector T1/ST2+ Th2 cells among CD3+CD4+ Th cells in the DLNs and lungs between anti-activin-A- and Ig-treated mice (unpublished data). In support, levels of the Th2 cell-recruiting chemokines CCL17 and CCL22 were not significantly altered between the two groups (Fig. 1 G). This suggested that the overall increase in Th2-mediated allergic responses upon in vivo activin-A depletion was not caused by increased Th2 effector cell trafficking but rather by an enhanced effector function of Th2 cells. To address this, we examined the effects of DLN cells obtained from anti-activin-A-treated mice (or Ig controls) on responses of co-cultured OVA-specific T cell receptor transgenic Th cells from DO11.10 mice (recognized by expression of the clonotypic receptor by the antibody KJ1-26 and hereafter referred to as KJ1-26+) to the OVA323-339 peptide. Indeed, DLN cells from anti-activin-A-treated mice lead to significantly increased proliferation of KJ1-26+CD4+ T responders to the OVA323-339 peptide (Fig. 1 H). These data further support decreased immune regulation upon blockade of endogenously produced activin-A in vivo. Overall, antibody-mediated depletion of activin-A during pulmonary allergen challenge enhanced allergen-specific Th2 responses and exacerbated allergic airway disease.
###end p 14
###begin title 15
Activin-A suppresses antigen-specific primary and effector Th2 responses
###end title 15
###begin p 16
###xml 647 655 647 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 A</xref>
###xml 730 738 730 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 A</xref>
###xml 354 358 <span type="species:ncbi:10090">mice</span>
Effector Th2 cell-mediated responses are essential for the development of allergic airway inflammation and asthmatic disease. Thus, we hypothesized that activin-A protects against allergic airway inflammation through suppression of antigen-specific Th2 effector responses. To examine this, we isolated OVA-primed Th2 effector cells from DLNs of allergic mice (sensitized with OVA/alum and challenged with OVA) and restimulated them ex vivo with OVA in the presence of r-activin-A or PBS (control). Indeed, r-activin-A treatment suppressed responses of OVA-primed Th2 effector cells, as shown by significantly decreased OVA-specific proliferation (Fig. 2 A) and significantly decreased concentrations of supernatant Th2 cytokines (Fig. 2 A). Similar to what was observed for IL-4 and IL-13, r-activin-A significantly decreased IL-10 production because, in this setting of Th2 effector responses, IL-10 operates mainly as a Th2 cytokine. In support, using the reverse approach, we demonstrated that blockade of either endogenously expressed activin-A or its critical signaling receptor, activin-like kinase (ALK) 4, resulted in significantly increased levels of IL-4, IL-13, and IL-10, and enhanced Th2 cell proliferation, as compared with Ig treatment (not depicted).
###end p 16
###begin p 17
###xml 0 73 0 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Activin-A suppresses antigen-specific primary and effector Th2 responses.</bold>
###xml 431 432 429 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 666 667 664 665 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 720 723 718 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 716 723 714 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rag1<sup>&#8722;/&#8722;</sup></italic>
###xml 797 798 795 796 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 909 910 905 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1024 1025 1020 1021 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1028 1029 1024 1025 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
###xml 584 588 <span type="species:ncbi:10090">mice</span>
###xml 775 779 <span type="species:ncbi:10090">mice</span>
###xml 917 921 <span type="species:ncbi:10090">mice</span>
Activin-A suppresses antigen-specific primary and effector Th2 responses. (A) DLN cells were harvested from OVA/alum-immunized and OVA-challenged BALB/c mice, and proliferation was measured after ex vivo OVA restimulation in the presence of PBS (designated as control) or r-activin-A (*, P = 0.0121). Results are shown as means +/- SEM from four separate experiments. Statistical significance was obtained by an unpaired Student's t test. IL-4 (**, P = 0.0070), IL-13 (*, P = 0.0103), and IL-10 (**, P = 0.0081) in supernatants are shown. (B) DLN cells from OVA/alum-immunized BALB/c mice were restimulated ex vivo with OVA in the presence of PBS or r-activin-A. CD4+ T cells were adoptively transferred into BALB/c-Rag1-/- recipients. Proliferation of DLN cells to OVA from mice that received CD4+ T cells treated with PBS or r-activin-A (***, P < 0.0001). The results are means +/- SEM of triplicate wells (n = 4-6 mice per group in two separate experiments). Statistical significance was obtained as described. (C) KJ1-26+CD4+ T cells were stimulated with OVA and irradiated APCs as indicated. Proliferation was measured (***, P < 0.0001). IL-4 (**, P = 0.0038) and IL-10 (**, P = 0.0073) are shown. Results are means +/- SEM of triplicate wells from four separate experiments.
###end p 17
###begin p 18
###xml 257 261 257 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rag1</italic>
###xml 261 264 261 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 361 369 361 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 B</xref>
###xml 571 579 571 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 B</xref>
###xml 275 279 <span type="species:ncbi:10090">mice</span>
We subsequently investigated whether r-activin-A treatment of Th2 effector cells would also render them suppressed during antigenic stimulation in vivo. To address this, r-activin-A- or PBS-treated Th2 effector cells were adoptively transferred into BALB/c-Rag1-/- recipient mice, which were later immunized with OVA in alum (experimental protocol described in Fig. 2 B). Adoptively transferred r-activin-A-treated Th2 effector cells retained a suppressed phenotype after in vivo antigenic stimulation, as shown by significantly decreased antigen-specific proliferation (Fig. 2 B).
###end p 18
###begin p 19
###xml 111 112 111 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 115 116 115 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 297 298 297 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 301 302 301 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 312 320 312 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 C</xref>
###xml 418 426 418 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 C</xref>
###xml 531 539 531 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 C</xref>
###xml 639 640 639 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 643 644 643 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 663 670 663 670 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 872 890 872 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">Ogawa et al., 2006</xref>
###xml 1045 1046 1045 1046 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1049 1050 1049 1050 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Subsequently, we investigated activin-A's effects on primary antigen-driven Th responses. We isolated LN KJ1-26+CD4+ T cells and stimulated them in vitro with antigen in the presence of r-activin-A. Treatment with r-activin-A resulted in significantly decreased OVA-induced proliferation of KJ1-26+CD4+ T cells (Fig. 2 C). In addition, IL-4 levels were decreased during r-activin-A treatment as compared with control (Fig. 2 C). The suppressive effect of r-activin-A was accompanied by significantly increased production of IL-10 (Fig. 2 C). Similarly, r-activin-A also significantly suppressed the robust proliferative responses of KJ1-26+CD4+ T cells to the OVA323-339 peptide and induced increased production of IL-10 (not depicted). We and other investigators have found that activin-A is produced during primary Th responses (50-500 pg/ml in Th stimulation cultures; Ogawa et al., 2006). As anticipated, addition of a neutralizing antibody to block endogenously produced activin-A resulted in significantly increased proliferation of KJ1-26+CD4+ T cells during OVA-driven stimulation, concomitant with decreased IL-10 levels, as compared with Ig treatment (a two- and fourfold increase, respectively). Similar results were obtained when ALK4 was blocked (a two- and threefold increase, respectively), indicating that the suppressive effects of activin-A were mainly mediated by ALK4. Hence, activin-A suppresses both primary and effector antigen-specific Th2 responses in vitro and renders Th2 effector cells hyporesponsive to immunization in vivo.
###end p 19
###begin title 20
###xml 50 51 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Activin-A induces the generation of regulatory CD4+ T cells that are suppressive in vitro and in vivo
###end title 20
###begin p 21
###xml 254 255 254 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 294 295 294 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 298 299 298 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 366 373 366 373 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 476 477 476 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 480 481 480 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 500 507 500 507 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 517 525 517 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 A</xref>
###xml 534 535 534 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 538 539 538 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 793 794 781 782 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 797 798 785 786 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 808 816 796 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 B</xref>
###xml 886 904 871 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">Chen et. al., 2003</xref>
###xml 906 922 891 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">Li et. al., 2007</xref>
###xml 1099 1100 1084 1085 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1103 1104 1088 1089 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1160 1175 1142 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, A and B</xref>
Subsequently, we investigated whether activin-A-mediated Th suppression is associated with induction of T cells with regulatory/suppressive function. To address this, we performed an in vitro suppression assay wherein we co-cultured activin-A-treated CD4+ T cells with untreated T cells (KJ1-26+CD4+ T cells) and examined the responses of the latter cells to the OVA323-339 peptide. r-activin-A-treated OVA-primed Th2 cells significantly suppressed the proliferation of KJ1-26+CD4+ T cells to the OVA323-339 peptide (Fig. 3 A). KJ1-26+CD4+ T cells cultured alone exhibited much higher, compared with the other groups, antigen-specific proliferative responses (approximately120,000 cpm). Moreover, r-activin-A-treated T cells significantly inhibited IL-4 and IL-13 release from responder KJ1-26+CD4+ T cells (Fig. 3 B). Treatment with TGF-beta1, a well-known immunosuppressive cytokine (Chen et. al., 2003; Li et. al., 2007), also conferred inhibitory effects on OVA-primed Th2 cells. This was shown by significantly decreased antigen-specific proliferation and cytokine release from responder KJ1-26+CD4+ T cells after co-culture with TGF-beta1-treated cells (Fig. 3, A and B). Overall, r-activin-A-treated antigen (OVA)-specific Th2 cells had essential features of regulatory T cells; i.e., they were suppressed during antigenic stimulation and suppressive toward antigen-driven responses of other Th cells in vitro.
###end p 21
###begin p 22
###xml 67 68 67 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 77 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Activin-A induces the generation of antigen-specific regulatory CD4<sup>+</sup> T cells.</bold>
###xml 218 219 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 256 257 253 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 260 261 257 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 318 325 315 322 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 545 546 540 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 877 878 867 868 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 951 952 941 942 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 955 956 945 946 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 987 990 977 980 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 983 990 973 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rag1<sup>&#8722;/&#8722;</sup></italic>
###xml 1112 1113 1102 1103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1181 1182 1171 1172 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1188 1189 1178 1179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1281 1282 1269 1270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1391 1398 1379 1386 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 1482 1483 1468 1469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1701 1702 1685 1686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 123 127 <span type="species:ncbi:10090">mice</span>
###xml 1289 1293 <span type="species:ncbi:10090">mice</span>
###xml 1380 1384 <span type="species:ncbi:10090">mice</span>
###xml 1490 1494 <span type="species:ncbi:10090">mice</span>
###xml 1709 1713 <span type="species:ncbi:10090">mice</span>
Activin-A induces the generation of antigen-specific regulatory CD4+ T cells. (A) DLN cells from OVA/alum-immunized BALB/c mice were restimulated ex vivo with OVA in the presence of PBS, r-activin-A, or rTGF-beta1. CD4+ T cells were co-cultured with KJ1-26+CD4+ T cells (2:1) in the presence of irradiated APCs and OVA323-339 peptide. Proliferation is shown (***, P < 0.0001; **, P = 0.0010). Results are shown as means +/- SEM of triplicate wells in two independent experiments. Statistical significance was calculated by an unpaired Student's t test. (B) IL-4 (**, P < 0.0001; ***, P < 0.0001), IL-13 (***, P < 0.0001; **, P = 0.0007), and IL-10 (P = 0.9903; P = 0.0815) in supernatants are shown. Results are means +/- SEM of duplicate wells in two separate experiments. Statistical significance was calculated as described. (C) r-activin-A-, rTGF-beta1-, or PBS-treated CD4+ T cells (obtained as in A) were adoptively transferred along with KJ1-26+CD4+ T cells (1:1) into BALB/c-Rag1-/- recipients. Recipients were immunized with OVA/alum, and DLN cells were harvested. (D) Flow cytometry panels of gated CD4+ T cells from recipients stained for KJ1-26. Absolute numbers of CD4+KJ1-26+ T cells in DLNs of recipients (**, P < 0.0001; ***, P < 0.0001). Values are means +/- SEM (n = 4-6 mice per group in two separate experiments). (E) Proliferation of DLN cells from recipient mice to OVA323-339 peptide is shown (**, P < 0.0001; ***, P < 0.0001). The results are means +/- SEM (n = 4-6 mice per group from two separate experiments). (F) IL-4 (**, P < 0.0001; ***, P < 0.0001), IL-13 (***, P < 0.0001; **, P = 0.0001), and IL-10 (P = 0.5253; P = 0.7871) in supernatants. Results are means +/- SEM (n = 4-6 mice per group from two separate experiments).
###end p 22
###begin p 23
###xml 49 50 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 256 257 256 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 293 294 293 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 297 298 297 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 333 336 333 336 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 329 336 329 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rag1<sup>&#8722;/&#8722;</sup></italic>
###xml 391 392 391 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 395 396 395 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 477 485 477 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 C</xref>
###xml 564 565 564 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 616 617 616 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 620 621 620 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 657 665 657 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 D</xref>
###xml 709 710 709 710 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 769 770 769 770 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 773 774 773 774 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 793 800 793 800 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 920 921 920 921 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 998 1006 998 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 E</xref>
###xml 1030 1031 1027 1028 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1105 1106 1102 1103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1109 1110 1106 1107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1146 1161 1143 1158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, D and E</xref>
###xml 1253 1260 1250 1257 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 1288 1289 1285 1286 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1292 1293 1289 1290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1388 1389 1382 1383 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1399 1407 1393 1401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 F</xref>
###xml 337 341 <span type="species:ncbi:10090">mice</span>
###xml 651 655 <span type="species:ncbi:10090">mice</span>
###xml 878 882 <span type="species:ncbi:10090">mice</span>
###xml 1140 1144 <span type="species:ncbi:10090">mice</span>
###xml 1324 1328 <span type="species:ncbi:10090">mice</span>
Next, we examined whether r-activin-A-treated CD4+ T cells were also suppressive toward responses by other Th cells in vivo. For this, we performed an in vivo suppression assay wherein we adoptively cotransferred r-activin-A (or PBS)-treated OVA-primed CD4+ T cells along with untreated KJ1-26+CD4+ T cells into recipient BALB/c-Rag1-/- mice and examined antigen-specific responses of KJ1-26+CD4+ T cells after immunization with OVA in alum (experimental protocol described in Fig. 3 C). Flow cytometry revealed that r-activin-A- but not PBS-treated OVA-primed CD4+ T cells decreased OVA-specific expansion of KJ1-26+CD4+ T cells in DLNs of recipient mice (Fig. 3 D). More importantly, r-activin-A-treated CD4+ T cells suppressed the ex vivo proliferation of DLN KJ1-26+CD4+ T cells to the OVA323-339 peptide, as shown by significantly decreased proliferation of DLN cells from mice that received r-activin-A-treated CD4+ T cells as compared with DLN cells from recipients of PBS-treated controls (Fig. 3 E). TGF-beta1-treated CD4+ T cells also inhibited OVA-specific expansion and proliferation of KJ1-26+CD4+ T cells in DLNs of recipient mice (Fig. 3, D and E). We also observed significantly decreased IL-4 and IL-13 levels in the supernatants of OVA323-339-stimulated responder KJ1-26+CD4+ T cells in DLNs obtained from mice that received either r-activin-A- or rTGF-beta1-treated CD4+ T cells (Fig. 3 F). It was not surprising that IL-10 remained unaltered, as this cytokine also functions as a Th2 cytokine in this setting. Hence, using both in vitro and in vivo suppression assays, we demonstrate that activin-A induces the generation of antigen-specific regulatory T cells that are suppressive toward responses of Th2 effector cells in vitro and upon adoptive transfer in vivo.
###end p 23
###begin title 24
Activin-A-induced suppression of Th responses is mediated by both IL-10 and TGF-beta1
###end title 24
###begin p 25
###xml 191 192 191 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 445 453 445 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 473 481 473 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 672 680 672 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 682 711 682 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">Hawrylowicz and O'Garra, 2005</xref>
###xml 844 845 844 845 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 963 971 963 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 B</xref>
###xml 1197 1205 1197 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 C</xref>
###xml 1173 1176 <span type="species:ncbi:31658">CFA</span>
###xml 1191 1195 <span type="species:ncbi:10090">mice</span>
Our studies so far have shown that activin-A suppresses antigen-driven Th responses. We next investigated whether this cytokine can also affect anti-CD3-driven T cell activation. Purified CD4+ T cells were stimulated with anti-CD3 in the presence of r-activin-A or PBS. Similar to our observations for Th2 effector responses, r-activin-A treatment also suppressed anti-CD3-driven Th stimulation, as shown by significantly reduced proliferation (Fig. 4 A) and IL-2 release (Fig. 4 A). Interestingly, activin-A-mediated suppression was accompanied by increased production of IL-10, a cytokine considered immunoregulatory in the context of, except for Th2, T cell responses (Fig. 4 A; Hawrylowicz and O'Garra, 2005). The immunosuppressive effects of activin-A were not caused by toxicity, as flow cytometry studies showed no increases in annexin V+ cells (not depicted). In fact, addition of rIL-2 reversed r-activin-A-mediated suppression of Th cell proliferation (Fig. 4 B). This also indicated that activin-A renders Th cells anergic. Notably, r-activin-A treatment also suppressed antigen (OVA)-specific in vitro proliferation of Th1 effector cells (obtained from DLNs of CFA/OVA-immunized mice; Fig. 4 C). Collectively, our results reveal that activin-A not only suppresses Th2 cell-associated responses but also inhibits Th1 cell activation.
###end p 25
###begin p 26
###xml 0 73 0 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Activin-A&#8211;induced suppression is partly dependent on IL-10 and TGF-&#946;1.</bold>
###xml 81 82 78 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 338 339 333 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 464 465 459 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 940 941 931 932 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1287 1288 1276 1277 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1432 1433 1418 1419 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1551 1552 1535 1536 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1666 1667 1650 1651 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1672 1673 1656 1657 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 710 713 <span type="species:ncbi:31658">CFA</span>
###xml 731 735 <span type="species:ncbi:10090">mice</span>
Activin-A-induced suppression is partly dependent on IL-10 and TGF-beta1. (A) CD4+ T cells were stimulated with anti-CD3 and irradiated APCs as indicated. Proliferation was measured. The results are means +/- SEM of triplicate wells from at least three separate experiments. Statistical significance was obtained by an unpaired Student's t test (***, P = 0.0009). IL-2 (***, P = 0.0004) and IL-10 (*, P = 0.0463) in supernatants are shown. (B) Proliferation of CD4+ T cells stimulated as in A in the presence of r-activin-A and rIL-2 as indicated (***, P < 0.0001; **, P = 0.0010; P = 0.9871). The results are means +/- SEM of triplicate wells from three separate experiments. (C) DLN cells, obtained from OVA/CFA-immunized BALB/c mice, were stimulated ex vivo with OVA as indicated. Proliferation was measured (***, P < 0.0001). The results are means +/- SEM of triplicate wells from three independent experiments. (D) Proliferation of CD4+ T cells stimulated with anti-CD3 and irradiated APCs with PBS or r-activin-A, as indicated (*, P = 0.0054; **, P = 0.0011; ***, P = 0.0012; ****, P = 0.0002). IL-2 (*, P = 0.0005; **, P = 0.0004; ***, P = 0.0003) in supernatants is shown. The results are means +/- SEM from two separate experiments. (E) Stimulated (anti-CD3/CD28 with rIL-2) CD4+ T cells from PBS-, r-activin-A-, or TGF-beta1-treated cultures were stained and analyzed by flow cytometry. Numbers indicate percentages of CD4+ gated cells positive for CD25 and Foxp3. Values are expressed as means +/- SEM from two separate experiments. (F) CD4+ T cells, stimulated as in A, stained with antibodies to CD3, CD4, and IL-10. Representative dot plots showing CD4+IL-10+ cells from cultures of PBS- or r-activin-A-treated cells. Numbers above boxed areas indicate the percentage of DLN cells in the outlined gate. Values are expressed as means +/- SEM from two separate experiments. FS, forward scatter.
###end p 26
###begin p 27
###xml 97 106 97 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figs. 2 C</xref>
###xml 111 114 111 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">4 A</xref>
###xml 366 374 366 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 D</xref>
###xml 512 513 512 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 516 517 516 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 886 894 882 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 D</xref>
###xml 999 1000 995 996 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1072 1073 1068 1069 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1076 1077 1072 1073 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
As our studies have demonstrated an increased production of IL-10 under certain immune settings (Figs. 2 C and 4 A), we next investigated the potential role of this cytokine in the immunosuppressive effects of activin-A. Blocking of IL-10, using an antibody against IL-10R, partially reversed r-activin-A-mediated suppression of proliferative Th effector responses (Fig. 4 D). Similarly, anti-IL-10R treatment partially reversed the suppressive effect of r-activin-A on antigen-driven primary responses of KJ1-26+CD4+ T cells so that r-activin-A- and anti-IL-10R-treated cells exhibited similar proliferation to PBS and anti-IL-10R-treated cells (132,300 +/- 6,515 cpm for PBS- and anti-IL-10R-treated cells vs. 120,300 +/- 7,752 cpm for r-activin-A- and anti-IL-10R-treated cells). However, blockade of IL-10 did not significantly affect activin-A-induced suppression of IL-2 release (Fig. 4 D). Importantly, blocking of IL-10 also partly reversed the suppressive effects of r-activin-A-induced CD4+ regulatory T cells (OVA-primed Th cells) on the proliferation of KJ1-26+CD4+ responder T cells (unpublished data).
###end p 27
###begin p 28
###xml 378 386 372 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 D</xref>
As blocking of IL-10 did not completely reverse the inhibitory effects of activin-A on Th responses, we hypothesized that other immunosuppressive cytokines (such as TGF-beta1) may also be involved. Addition of a blocking antibody against TGF-beta1 partially reversed activin-A-mediated suppression of Th cell proliferation, whereas it inhibited the suppression of IL-2 release (Fig. 4 D). Notably, addition of both anti-IL-10R and anti-TGF-beta1 antibodies completely reversed activin-A-induced suppression of Th responses, indicating a synergistic effect.
###end p 28
###begin p 29
###xml 236 257 236 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">Fontenot et al., 2003</xref>
###xml 259 276 259 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">Hori et al., 2003</xref>
###xml 278 298 278 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib63">Vignali et al., 2008</xref>
###xml 360 361 360 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 433 434 433 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 438 439 438 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 442 443 442 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 653 654 646 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 657 658 650 651 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 694 702 685 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 E</xref>
###xml 766 783 757 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">Chen et al., 2003</xref>
###xml 785 806 776 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">Fontenot et al., 2003</xref>
###xml 808 829 799 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">Davidson et al., 2007</xref>
###xml 881 882 872 873 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 886 887 877 878 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 892 893 883 884 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 954 961 945 952 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 1040 1041 1031 1032 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1046 1047 1037 1038 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1497 1504 1480 1487 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 1720 1721 1699 1700 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1830 1831 1797 1798 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1834 1835 1801 1802 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1866 1874 1833 1841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 F</xref>
###xml 1947 1948 1914 1915 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1993 2000 1960 1967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figs. 2</xref>
###xml 2005 2006 1972 1973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">4</xref>
###xml 2072 2073 2036 2037 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2076 2077 2040 2041 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 922 926 <span type="species:ncbi:10090">mice</span>
###xml 1254 1258 <span type="species:ncbi:10090">mice</span>
###xml 1463 1467 <span type="species:ncbi:10090">mice</span>
Examination of the phenotype of the activin-A-induced regulatory T cells revealed that these cells lacked expression of Forkhead box p3 (Foxp3), the transcription factor that drives differentiation of certain regulatory T cell subsets (Fontenot et al., 2003; Hori et al., 2003; Vignali et al., 2008). In fact, flow cytometry analysis of anti-CD3-stimulated CD4+ T cells showed that there were no differences in the frequency of Foxp3+CD25+CD4+ T cells after r-activin-A treatment as compared with control (280,300 +/- 15,150 cells for r-activin-A vs. 335,200 +/- 18,950 cells for PBS). In contrast, rTGF-beta1 treatment induced a greater number of Foxp3+CD4+ T cells (546,700 +/- 20,280 cells; Fig. 4 E) as compared with PBS treatment, as also previously described (Chen et al., 2003; Fontenot et al., 2003; Davidson et al., 2007). In addition, r-activin-A treatment of sorted (CD4+CD25-CD62L+) naive T cells from DO11.10 mice during stimulation with OVA323-339 peptide-loaded bone marrow-derived DCs did not induce increased numbers of CD4+Foxp3+ T cells (12,420 +/- 2,133 cells for r-activin-A vs. 14,600 +/- 1,456 cells for PBS). Similarly, treatment with r-activin-A during restimulation with OVA ex vivo of DLN cells obtained from OVA-primed BALB/c mice did not induce significantly increase Foxp3 expression (34,570 +/- 3,123 cells for r-activin-A vs. 30,090 +/- 2,827 cells for PBS treatment). Also, activin-A treatment of DLN cells from immunized DO11.10 mice during restimulation with OVA323-339 peptide ex vivo did not induce a significant increase in Foxp3 expression, as compared with PBS (30,700 +/- 2,170 cells for r-activin-A vs. 28,250 +/- 2,350 cells for PBS). Nevertheless, r-activin-A treatment of CD4+ T cells (stimulated with either anti-CD3 or antigen) resulted in an approximately2.5-fold induction of IL-10+CD4+ T cells as compared with PBS (Fig. 4 F). These findings are in agreement with the increased IL-10 levels in CD4+ T cell cultures upon r-activin-A treatment (Figs. 2 and 4). However, rTGF-beta1-treatment did not significantly alter IL-10+CD4+ T cell numbers (not depicted), suggesting that, at least in our experimental settings, these two cytokines induce distinct regulatory T cell subsets. Collectively, our findings suggest that activin-A can exert a broad immunosuppressive effect on Th effector responses in vitro that is dependent on both IL-10 and TGF-beta1 production.
###end p 29
###begin title 30
Activin-A-induced regulatory T cells protect against allergic airway disease
###end title 30
###begin p 31
###xml 197 198 197 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 223 229 223 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3</xref>
###xml 329 337 329 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 A</xref>
###xml 398 399 398 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 499 505 499 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5</xref>
###xml 680 681 680 681 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 748 749 748 749 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 759 767 759 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 B</xref>
###xml 891 892 891 892 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 956 964 956 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 C</xref>
###xml 1084 1092 1084 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 D</xref>
###xml 1143 1151 1143 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 D</xref>
###xml 1214 1215 1214 1215 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 453 461 <span type="species:ncbi:405018">cardinal</span>
###xml 613 617 <span type="species:ncbi:10090">mice</span>
###xml 707 711 <span type="species:ncbi:10090">mice</span>
###xml 838 842 <span type="species:ncbi:10090">mice</span>
###xml 1169 1173 <span type="species:ncbi:10090">mice</span>
We next asked whether activin-A-induced regulatory T cells can confer protection against Th-mediated disease in vivo. To address this, we adoptively transferred r-activin-A (or control)-treated CD4+ T cells (obtained as in Fig. 3) into BALB/c mice before OVA/alum immunization and OVA aerosol challenge (experimental protocol in Fig. 5 A). Remarkably, transfer of r-activin-A-treated OVA-primed CD4+ T cells resulted in a significant attenuation of all cardinal features of allergic airway disease (Fig. 5). This was demonstrated by significantly decreased total numbers of BAL cells and, notably, eosinophils in mice adoptively transferred with r-activin-A-treated OVA-primed CD4+ T cells as compared with mice transferred with control-treated CD4+ T cells (Fig. 5 B). More importantly, there was a dramatic decrease in AHR responses in mice that received r-activin-A-treated OVA-primed CD4+ T cells that reached levels similar to those of alum controls (Fig. 5 C). A significant decrease (approximately threefold in histological score) was also observed in leukocytic infiltration (Fig. 5 D) and in mucus secretion (approximately threefold; Fig. 5 D) in the lungs of mice transferred with r-activin-A-treated CD4+ T cells, as compared with controls.
###end p 31
###begin p 32
###xml 0 96 0 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Activin-A&#8211;induced regulatory T cells protect from allergic airway disease upon transfer in vivo.</bold>
###xml 104 105 104 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 130 136 130 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3</xref>
###xml 349 350 349 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 427 428 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 543 544 541 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 652 653 650 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 798 799 796 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1072 1073 1068 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1382 1383 1372 1373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1564 1565 1552 1553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1658 1659 1646 1647 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1664 1665 1652 1653 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1711 1712 1699 1700 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 1843 1844 1831 1832 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1849 1850 1837 1838 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1854 1855 1842 1843 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1895 1896 1883 1884 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1994 1995 1980 1981 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 219 223 <span type="species:ncbi:10090">mice</span>
###xml 299 303 <span type="species:ncbi:10090">mice</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 660 664 <span type="species:ncbi:10090">mice</span>
###xml 1080 1084 <span type="species:ncbi:10090">mice</span>
###xml 1390 1394 <span type="species:ncbi:10090">mice</span>
###xml 1531 1535 <span type="species:ncbi:10090">mice</span>
###xml 1572 1576 <span type="species:ncbi:10090">mice</span>
###xml 1691 1695 <span type="species:ncbi:10090">mice</span>
###xml 1873 1877 <span type="species:ncbi:10090">mice</span>
###xml 2002 2006 <span type="species:ncbi:10090">mice</span>
Activin-A-induced regulatory T cells protect from allergic airway disease upon transfer in vivo. (A) CD4+ T cells (obtained as in Fig. 3) were treated with either PBS or r-activin-A and adoptively transferred to BALB/c mice before OVA/alum immunization and OVA challenge. (B) BAL differentials from mice that received r-activin-A- or PBS-treated CD4+ T cells, or from the alum controls. Results are expressed as means +/- SEM (n = 5-7 mice per group in two separate experiments). Statistical significance was obtained by an unpaired Student's t test (*, P = 0.0407; ***, P = 0.0007). (C) AHR is depicted. Results shown for PenH are expressed as means (n = 5-7 mice per group in two separate experiments). Data were analyzed by two-way ANOVA for repeated measures, followed by an unpaired Student's t test (*, P = 0.0341; **, P = 0.0003; ***, P = 0.0004; ****, P = 0.0017). (D) Representative photomicrographs and histological scores of H&E-stained (***, P < 0.0001) and PAS-stained (***, P = 0.0004) sections. Error bars depict means of groups. Results are means +/- SEM (n = 5-7 mice per group in two independent experiments). Bars, 100 microm. (E) DLN cells were restimulated ex vivo with OVA. Proliferation was measured (***, P = 0.0002). IL-4 (***, P < 0.0001), IL-13 (***, P < 0.0001), and IL-10 (***, P = 0.0008) in supernatants are shown. Results are shown as means +/- SEM (n = 5-7 mice per group in two separate experiments). (F) OVA-specific IgE (**, P = 0.0009), IgG1 (P = 0.1259), and IgG2a (P = 0.4556) in the sera of mice. Results are means +/- SEM (n = 5-7 mice per group in two independent experiments). (G) Flow cytometry panels of gated CD3-CD11c+ DLN cells from recipient mice stained for I-Ad. Numbers above boxed areas indicate the percentage of DLN cells in the outlined gate. The mean fluorescence intensity (MFI) of CD3-CD11c+I-Ad+ cells in DLNs of mice that received CD4+ T cells treated with PBS or r-activin-A is depicted (***, P < 0.0001). Values are means +/- SEM (n = 5-7 mice per group in two separate experiments). Eos, eosinophils; FS, forward scatter; LMs, lymphomononuclears; Macs, macrophages; Neuts, neutrophils.
###end p 32
###begin p 33
###xml 95 96 95 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 169 177 169 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 E</xref>
###xml 262 270 262 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 E</xref>
###xml 335 336 335 336 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 443 451 443 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 F</xref>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
In accordance, DLN cells obtained from mice adoptively transferred with r-activin-A-treated CD4+ T cells exhibited significantly decreased proliferation to OVA ex vivo (Fig. 5 E) and produced significantly decreased levels of supernatant IL-4, IL-13, and IL-10 (Fig. 5 E). More importantly, adoptive transfer of r-activin-A-treated CD4+ T cells significantly decreased OVA-specific IgE levels, a critical clinical feature of allergic disease (Fig. 5 F).
###end p 33
###begin p 34
###xml 263 279 263 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">Kim et al., 2007</xref>
###xml 281 305 281 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib38">O'Garra and Vieira, 2007</xref>
###xml 307 333 307 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib54">Sakaguchi and Powrie, 2007</xref>
###xml 395 396 395 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 420 421 420 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 543 544 543 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 624 625 624 625 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 662 670 662 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 G</xref>
###xml 956 957 956 957 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 568 572 <span type="species:ncbi:10090">mice</span>
DCs are essential for the differentiation and activation of Th responses, and several studies have demonstrated that regulatory T cell subsets can suppress immune-mediated disease through inhibition of the antigen presentation machinery and/or maturation of DCs (Kim et al., 2007; O'Garra and Vieira, 2007; Sakaguchi and Powrie, 2007). Interestingly, examination of the MHC class II molecule I-Ad expression on DLN CD11c+ DCs showed a striking decrease (an approximately ninefold difference, as shown by the mean fluorescence intensity) in I-Ad expression on DCs from mice adoptively transferred with r-activin-A-treated CD4+ T cells, as compared with controls (Fig. 5 G). In support, we observed a decrease in CD86 expression (not depicted). Collectively, our data revealed that activin-A-induced antigen-specific regulatory T cells can protect from allergic airway disease after transfer in vivo, and this is associated with decreased maturation of CD11c+ DCs in lung DLNs.
###end p 34
###begin title 35
Administration of activin-A in vivo suppresses experimental allergic asthma
###end title 35
###begin p 36
###xml 577 585 577 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 A</xref>
###xml 723 731 723 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 B</xref>
###xml 849 857 837 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 C</xref>
###xml 904 912 880 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 C</xref>
###xml 267 271 <span type="species:ncbi:10090">mice</span>
###xml 664 668 <span type="species:ncbi:10090">mice</span>
###xml 950 954 <span type="species:ncbi:10090">mice</span>
Based on our data on the suppressive roles of activin-A and activin-A-induced regulatory T cells on Th2 effector responses as well as on the effects of activin-A blockade during allergen challenge, we next examined whether administration of r-activin-A to sensitized mice would protect from disease induction. Indeed, systemic (i.p.) administration of r-activin-A to OVA/alum-immunized animals right before each OVA aerosol challenge resulted in significantly decreased total numbers of cells, and most importantly, eosinophils in the BAL, as compared with treatment with PBS (Fig. 6 A). Moreover, AHR responses were significantly decreased in r-activin-A-treated mice and reached levels similar to those of alum controls (Fig. 6 B). A significant decrease (approximately1.5-fold in histological score) was also observed in leukocytic infiltration (Fig. 6 C) and in mucus secretion (approximately2-fold; Fig. 6 C) in the lungs of r-activin-A-treated mice, as compared with PBS controls.
###end p 36
###begin p 37
###xml 0 120 0 120 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo administration of r-activin-A during pulmonary allergen challenge is protective against allergic airway disease.</bold>
###xml 244 245 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 393 394 391 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 469 470 467 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 615 616 613 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 861 862 857 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1159 1160 1149 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1345 1346 1333 1334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 148 152 <span type="species:ncbi:10090">mice</span>
###xml 252 256 <span type="species:ncbi:10090">mice</span>
###xml 477 481 <span type="species:ncbi:10090">mice</span>
###xml 869 873 <span type="species:ncbi:10090">mice</span>
###xml 1167 1171 <span type="species:ncbi:10090">mice</span>
###xml 1303 1307 <span type="species:ncbi:10090">mice</span>
###xml 1353 1357 <span type="species:ncbi:10090">mice</span>
In vivo administration of r-activin-A during pulmonary allergen challenge is protective against allergic airway disease. (A) BAL differentials from mice treated with r-activin-A or PBS, or from the alum controls are expressed as means +/- SEM (n = 4-6 mice per group in two separate experiments; **, P = 0.0021; ***, P < 0.0001). Statistical significance was obtained by an unpaired Student's t test. (B) AHR is depicted. Results shown for PenH are expressed as means (n = 4-6 mice per group in two separate experiments). Data were analyzed by two-way ANOVA for repeated measures, followed by an unpaired Student's t test (*, P = 0.0095; **, P = 0.0054). (C) Representative photomicrographs and histological scores of H&E-stained (**, P = 0.0085) and PAS-stained (**, P = 0.0015) sections. Error bars depict means of groups. Results are shown as means +/- SEM (n = 4-6 mice per group in two separate experiments). Bars, 100 microm. (D) DLN cells were restimulated ex vivo with OVA. Proliferation was measured (***, P < 0.0001). IL-4 (***, P < 0.0001), IL-13 (***, P < 0.0001), and IL-10 (***, P < 0.0001) in supernatants are shown. Results are means +/- SEM (n = 4-6 mice per group from two independent experiments). (E) OVA-specific IgE (*, P = 0.0119), IgG1 (**, P = 0.0081), and IgG2a in the sera of mice. Results are shown as means +/- SEM (n = 4-6 mice per group in two independent experiments). Eos, eosinophils; LMs, lymphomononuclears; Macs, macrophages; Neuts, neutrophils.
###end p 37
###begin p 38
###xml 129 137 129 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 D</xref>
###xml 235 243 235 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 D</xref>
###xml 373 381 373 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 E</xref>
###xml 35 39 <span type="species:ncbi:10090">mice</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
Similarly, DLN cells obtained from mice treated with r-activin-A exhibited significantly decreased proliferation to OVA ex vivo (Fig. 6 D) and produced decreased levels of IL-4, IL-13, and IL-10, as compared with PBS-treated controls (Fig. 6 D). In addition, OVA-specific IgG1 and IgE levels were decreased, whereas IgG2a levels were increased after r-activin-A treatment (Fig. 6 E). Hence, administration of r-activin-A in Th2-primed mice during pulmonary allergen challenge is protective against allergic airway disease induction.
###end p 38
###begin title 39
Decreased expression of activin-A signaling components in allergic asthma
###end title 39
###begin p 40
###xml 328 336 328 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 A</xref>
###xml 455 463 455 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 A</xref>
###xml 532 533 532 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 600 601 600 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 706 714 706 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 B</xref>
###xml 895 903 895 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 A</xref>
###xml 923 931 923 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 B</xref>
###xml 1105 1113 1105 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 B</xref>
Based on the aforementioned findings, one would expect that activin-A production would be down-regulated during aberrant inflammatory processes such as those occurring in allergic asthma. However, we observed increased activin-A expression in lung biopsies from individuals with mild asthma as compared with healthy volunteers (Fig. 7 A, left). Activin-A expression was mainly localized in bronchial epithelial cells and subepithelial inflammatory cells (Fig. 7 A, bottom left). A significant increase in the percentage of activin-A+ bronchial epithelial cells, as well as in the numbers of activin-A+ subepithelial cells, was observed in lung biopsies from asthmatics as compared with healthy volunteers (Fig. 7 B). Quite the opposite was evident regarding the expression of activin-A's type I receptor, ALK4, which was significantly decreased in subepithelial infiltrating inflammatory cells (Fig. 7 A, bottom right; and Fig. 7 B). Additionally, the levels of Act-RIIA were significantly decreased, both in bronchial epithelial cells and in subepithelial inflammatory cells, in the lungs of asthmatics (Fig. 7 B). Similarly, we detected decreased expression of Act-RIIB in the lungs of asthmatics (unpublished data). Thus, although activin-A is increased in asthmatic lungs, the expression of its receptors in infiltrating immune cells is markedly reduced, suggesting a down-regulation of its signaling pathway that may lead to reduced suppression of the allergic inflammatory response.
###end p 40
###begin p 41
###xml 0 76 0 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Decreased expression of activin-A's signaling components in allergic asthma.</bold>
###xml 557 558 557 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 590 591 590 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 701 702 697 698 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 725 726 721 722 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 740 741 736 737 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 804 805 800 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 836 837 832 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 981 982 977 978 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1004 1005 1000 1001 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1036 1037 1032 1033 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1364 1365 1358 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
Decreased expression of activin-A's signaling components in allergic asthma. (A) Representative photomicrographs showing expression of activin-A and ALK4 in bronchial biopsies from healthy individuals and asthmatics. The specific staining for activin-A and ALK4 is depicted in red, whereas nuclei are blue (in activin-A photos). Red arrows indicate positively stained epithelial cells and black arrows point to positively stained subepithelial cells. Photomicrographs are representative from experiments performed on lung biopsies obtained from asthmatics (n = 15) and healthy individuals (n = 6). Immunostaining was performed once for each lung section. Bars, 100 microm. (B) Percentages of activin-A+ (**, P = 0.0355), ALK4+, and act-RIIA+ (***, P = 0.0008) bronchial epithelial cells from asthmatics (n = 15) or healthy individuals (n = 6). For each biopsy, data were obtained counting positively stained epithelial cells along the entire basement membrane. Numbers of activin-A+ (*, P = 0.0045), ALK4+ (**, P = 0.0011), and act-RIIA+ (***, P = 0.0007) subepithelial cells were determined by counting the entire section in each biopsy and are expressed as cells per square millimeter. Immunostaining was performed once for each lung section. Cell counts are presented as medians +/- interquartile range. Statistical analysis was performed with the Mann-Whitney U test.
###end p 41
###begin title 42
DISCUSSION
###end title 42
###begin p 43
###xml 108 134 108 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib67">Werner and Alzheimer, 2006</xref>
Activin-A has been mainly studied in developmental, fibrotic, and monocyte-mediated inflammatory processes (Werner and Alzheimer, 2006). In the present study, our findings reveal that activin-A is a suppressive cytokine for Th-mediated immunity. In fact, we demonstrate for the first time, to our knowledge, that activin-A induces the generation of antigen-specific regulatory T cells that suppress responses by effector Th2 cells and, more importantly, transfer protection against Th2-associated allergic airway disease in vivo. Notably, we show that activin-A-induced regulation also affects Th1-driven responses, pointing to a broader immunosuppressive role for this cytokine.
###end p 43
###begin p 44
###xml 768 769 768 769 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 772 773 772 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1359 1360 1359 1360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1698 1716 1698 1716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">Ogawa et al., 2008</xref>
###xml 511 519 <span type="species:ncbi:405018">cardinal</span>
###xml 743 747 <span type="species:ncbi:10090">mice</span>
###xml 1628 1633 <span type="species:ncbi:10090">mouse</span>
###xml 2468 2472 <span type="species:ncbi:10090">mice</span>
Initially, our findings demonstrated that antibody-mediated depletion of activin-A during the clinically relevant phase of pulmonary allergen challenge resulted in significant exacerbation of Th2-mediated allergic airway disease (including increased AHR, BAL eosinophilia, Th2 cytokine and chemokine secretion, and OVA-specific systemic Th2 and antibody responses). Importantly, blockade of activin-A during OVA challenge resulted in a rapid (only after three daily doses of anti-activin-A) exacerbation of all cardinal features of the asthmatic disease. This indicated that endogenously produced activin-A is protective against allergic Th2 cell-mediated responses in the lung. In support, we found that DLN cells from anti-activin-A-treated mice cultured with KJ1-26+CD4+ T cells induced significantly heightened proliferative responses of the latter cells, pointing to decreased immune regulation. This was also evident by the significantly increased levels of Th2 cytokines. Concomitant up-regulation of IL-10 in these cultures can be explained either by the amplified Th2-mediated response or by the activation of regulatory mechanisms that are struggling to control the enhanced inflammation. We cannot exclude the possibility of an activin-A-mediated effect on lung epithelial and smooth muscle cells as well. Nevertheless, r-activin-A treatment of CD4+ T cells rendered them suppressive, as they inhibited Th2 effector cell responses when adoptively transferred in vivo. This latter experimental approach uncovered the effects of r-activin-A on immune cells only. In another study, activin-A neutralization in vivo by a mouse monoclonal antibody resulted in decreased antigen-specific IgE (Ogawa et al., 2008). The observed differences could be caused by the fact that the investigators of the latter study used a different experimental protocol that involved several OVA/alum immunizations and a single challenge, whereas they depleted activin-A not only during challenge but at both phases of the allergic response. Alternatively, or in conjunction, these differences may be, at least partly, caused by the use of different activin-A neutralizing antibodies. For example, it is possible that these antibodies blocked distinct activin-A epitopes, leading to different receptor-mediated responses. Nevertheless, in support of the suppressive effects of endogenous activin-A on IgE responses, we showed that systemic administration of r-activin-A into allergic mice right before pulmonary OVA challenge induced a striking (more than threefold) decrease in OVA-specific IgE levels. This was accompanied by significantly suppressed Th2 systemic responses and protection against allergic airway disease. Collectively, our data reveal that administration of r-activin-A can be an effective therapeutic protocol for Th2-driven experimental asthma.
###end p 44
###begin p 45
###xml 238 256 238 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Hardy et al., 2006</xref>
###xml 480 499 480 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Hardy et al. (2006)</xref>
###xml 676 693 676 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib61">Vale et al., 1988</xref>
###xml 695 716 695 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">Harrison et al., 2005</xref>
###xml 718 740 718 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib55">Xia and Schneyer, 2009</xref>
###xml 879 901 879 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib52">Rosendahl et al., 2001</xref>
###xml 903 925 903 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib53">Rosendahl et al., 2002</xref>
###xml 927 951 927 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">Kariyawasam et al., 2008</xref>
###xml 850 854 <span type="species:ncbi:10090">mice</span>
###xml 859 865 <span type="species:ncbi:9606">humans</span>
In a different study, local (pulmonary) administration of follistatin, an inhibitor of activin-A, during allergic airway inflammation decreased Th2 cytokines and mucus production, pointing to proinflammatory effects of activin-A locally (Hardy et al., 2006). The different findings between our studies and the aforementioned ones may be, at least partly, caused by the use of distinct activin-A inhibitors. We administered a specific anti-activin-A neutralizing antibody, whereas Hardy et al. (2006) administered follistatin, an approach that does not directly address the effects of activin-A, as follistatin neutralizes all activins and certain bone morphogenetic proteins (Vale et al., 1988; Harrison et al., 2005; Xia and Schneyer, 2009). Moreover, considering that other activins and bone morphogenetic proteins are also induced in the lungs of mice and humans with asthma (Rosendahl et al., 2001; Rosendahl et al., 2002; Kariyawasam et al., 2008), it is plausible that the observed differences are also related to other follistatin functions, such as the inhibition of these proteins.
###end p 45
###begin p 46
###xml 663 684 660 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib62">Veldhoen et al., 2006</xref>
###xml 801 824 798 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib69">Wyss-Coray et al., 1997</xref>
###xml 826 842 823 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">Luo et al., 2007</xref>
###xml 913 934 907 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib62">Veldhoen et al., 2006</xref>
###xml 1005 1023 996 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">Johns et al., 1991</xref>
###xml 1025 1047 1016 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">Kuruvilla et al., 1991</xref>
###xml 1049 1071 1040 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">Johns and Sriram, 1993</xref>
###xml 1134 1152 1122 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">Allen et al., 1990</xref>
###xml 1154 1174 1142 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">Brandes et al., 1991</xref>
###xml 1334 1360 1322 1348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib51">Rosenbaum and Angell, 1995</xref>
###xml 1362 1381 1350 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">Koedel et al., 1996</xref>
###xml 1423 1442 1411 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Hardy et al. (2006)</xref>
Activin-A may also exert distinct in vivo effects depending on the route of administration or the site of overexpression. In fact, in contrast to the suppressive effects of systemic activin-A administration on allergic disease, we have showed that local (pulmonary) administration of r-activin-A enhances Th2 effector responses and exacerbates certain disease features (unpublished data). These findings point to proinflammatory effects of excessive amounts of activin-A locally, a feature shared by several cytokines, including immunoregulatory ones. For example, TGF-beta1 blockade locally prevents the onset of experimental autoimmune encephalomyelitis (EAE) (Veldhoen et al., 2006), and overexpression in the brain results in more severe EAE, pointing to a proinflammatory role for this cytokine (Wyss-Coray et al., 1997; Luo et al., 2007). In contrast, TGF-beta1 neutralization systemically exacerbates EAE (Veldhoen et al., 2006), and systemic (i.p.) TGF-beta1 administration protects from disease (Johns et al., 1991; Kuruvilla et al., 1991; Johns and Sriram, 1993). TGF-beta1 acts similarly in models of rheumatoid arthritis (Allen et al., 1990; Brandes et al., 1991). Dual effects depending on the route of administration have been also described for IL-10 in models of pneumococcal meningitis and endotoxin-induced uveitis (Rosenbaum and Angell, 1995; Koedel et al., 1996). Collectively, our studies and those by Hardy et al. (2006) emphasize the complex roles of activin-A in the regulation of the immune response.
###end p 46
###begin p 47
###xml 237 238 237 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 241 242 241 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 261 268 261 268 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 418 419 418 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 423 424 423 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 429 430 429 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 505 506 502 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 510 511 507 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 528 529 525 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 533 534 530 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 539 540 536 537 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 622 640 619 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">Huber et al., 2009</xref>
###xml 800 801 794 795 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 806 807 800 801 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Importantly, our data reveal that activin-A's immunosuppressive effects were associated with induction of antigen-specific regulatory T cells. Strikingly, these activin-A-induced suppressor T cells inhibited the robust response of KJ1-26+CD4+ T cells to the OVA323-339 peptide in vitro and suppressed responses of other untreated Th cells upon adoptive cotransfer in vivo. Activin-A-induced regulatory T cells were CD4+CD25-Foxp3-. A very recent study demonstrated that TGF-beta1-induced conversion of CD4+CD25- T cells into CD4+CD25+Foxp3+ T cells in vitro could be further enhanced if activin-A was added in the medium (Huber et al., 2009). However, activin-A was not essential for TGF-beta1-induced Foxp3 expression, as neutralization by follistatin or anti-activin-A antibody had no effect on CD4+Foxp3+ T cell numbers. Moreover, the presence of low levels of TGF-beta1 in activin-A-treated cultures was essential for Foxp3 induction, supporting the notion that activin-A alone does not induce considerable Foxp3 expression.
###end p 47
###begin p 48
###xml 64 65 64 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 201 202 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 716 732 716 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib68">Wills-Karp, 1999</xref>
Notably, activin-A induced the generation of a population of CD4+IL-10+ T cells, possibly representing Tr1-like T regulatory cells. In support, activin-A treatment increased IL-10 levels in primary CD4+ T cell cultures. Moreover, our in vitro blocking studies revealed that enhanced IL-10 production represents one of the mechanisms of activin-A-induced Th suppression. However, IL-10 levels were unaltered or even decreased during activin-A-mediated suppression of secondary Th2 effector responses. This should not come as a surprise, because, in this setting, IL-10 (along with IL-4 and IL-13) acts predominantly as part of the effector Th2 cytokine profile and its levels follow the general Th2 cell suppression (Wills-Karp, 1999).
###end p 48
###begin p 49
###xml 536 555 533 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">Meiron et al., 2008</xref>
In addition, activin-A may induce other suppressive Th cell populations. This possibility explains our finding that blocking of IL-10 did not completely reverse the suppressive function of activin-A-induced regulatory Th cells. Furthermore, TGF-beta1 blockade also partially reversed activin-A-mediated Th suppression. Overall, it is conceivable that activin-A induces both IL-10-producing regulatory T cells and other non-IL-10-producing suppressor T cells. The chemokine CXCL12 was recently found to inhibit EAE in a similar fashion (Meiron et al., 2008).
###end p 49
###begin p 50
###xml 359 360 359 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 447 448 447 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 644 666 644 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib50">Roncarolo et al., 2006</xref>
###xml 668 681 668 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib58">Shevach, 2006</xref>
###xml 683 709 683 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib54">Sakaguchi and Powrie, 2007</xref>
Our present studies also revealed that activin-A-induced regulatory T cells can confer protection against AHR and allergic airway disease after adoptive transfer in vivo. In addition, activin-A-induced regulatory T cells suppress Th2 effector responses and, of clinical relevance, decrease allergen-specific IgE. Besides naturally occurring or inducible Foxp3+ T regulatory cells, several studies have shown the existence of antigen-specific Foxp3- suppressor T cells that are of critical importance, as they confer protection against immune-mediated diseases, i.e., in experimental models of multiple sclerosis and inflammatory bowel disease (Roncarolo et al., 2006; Shevach, 2006; Sakaguchi and Powrie, 2007). Hence, the emergence of factors, such as activin-A, that induce suppressor T cells protective against Th-linked diseases is of critical therapeutic importance.
###end p 50
###begin p 51
###xml 377 378 377 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 567 587 567 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib57">Segerer et al., 2008</xref>
###xml 366 371 <span type="species:ncbi:10090">mouse</span>
###xml 436 441 <span type="species:ncbi:9606">human</span>
Interestingly, the suppressive effects of activin-A-treated T cells were associated with a striking decrease of DC maturation in lung DLNs. Thus, it is plausible that activin-A also suppresses Th responses through regulation of DC function. In fact, activin-A induces in vitro a dramatic reduction on both MHC class II and CD86 co-stimulatory molecule expression on mouse CD11c+ DCs (unpublished data). In support, recent studies using human DCs have shown that activin-A prevents cytokine-induced HLA-DR up-regulation and promotes a tolerance-inducing DC phenotype (Segerer et al., 2008).
###end p 51
###begin p 52
###xml 320 342 320 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib52">Rosendahl et al., 2001</xref>
###xml 344 361 344 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Hardy et al. 2006</xref>
###xml 363 389 363 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">Karagiannidis et al., 2006</xref>
###xml 391 409 391 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">Ogawa et al., 2006</xref>
###xml 607 626 604 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">Chakir et al., 2003</xref>
###xml 628 651 625 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">Flood-Page et al., 2003</xref>
###xml 698 717 691 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib44">Ousman et al., 2007</xref>
###xml 736 756 729 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib70">Xanthou et al., 2007</xref>
###xml 1478 1479 1471 1472 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1483 1484 1476 1477 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1561 1581 1554 1574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">Kearley et al., 2005</xref>
###xml 314 318 <span type="species:ncbi:10090">mice</span>
###xml 1507 1511 <span type="species:ncbi:10090">mice</span>
We were initially surprised that bronchial epithelial and infiltrating subepithelial cells in lung biopsies from asthmatic individuals exhibited enhanced activin-A expression. Our findings, as well as those from other studies, also revealed increased activin-A expression by Th2 cells and in the lungs of allergic mice (Rosendahl et al., 2001; Hardy et al. 2006; Karagiannidis et al., 2006; Ogawa et al., 2006). Nevertheless, it is not unusual to have increased expression of immunosuppressive mediators during active inflammatory conditions. For example, TGF-beta1 is increased in the lungs of asthmatics (Chakir et al., 2003; Flood-Page et al., 2003), whereas up-regulation of alphaB-crystallin (Ousman et al., 2007) and osteopontin (Xanthou et al., 2007) is observed in multiple sclerosis and asthma, respectively. Importantly, the increase in activin-A was counterbalanced by decreased expression of activin-A's receptors, ALK4 and Act-RIIA and -RIIB, in infiltrating mononuclear cells of asthmatics. This is indicative of reduced activin-A signaling in infiltrating leukocytes, pointing to decreased immunoregulation. In support, blockade of ALK4 significantly enhanced Th2 responses in our experiments. Thus, activin-A up-regulation in the allergen-challenged lung may be part of an inherent protective mechanism, as also suggested by the exacerbation of allergic airway disease upon activin-A neutralization before challenge. Finally, adoptive transfers of regulatory CD4+CD25+ T cells in sensitized mice not only protected from allergic airway disease (Kearley et al., 2005) but also resulted in significant increase in lung activin-A levels (unpublished data).
###end p 52
###begin p 53
###xml 203 221 200 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib41">Ogawa et al., 2000</xref>
###xml 223 249 220 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib67">Werner and Alzheimer, 2006</xref>
###xml 251 266 248 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">Le et al., 2007</xref>
###xml 268 286 265 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">Ogawa et al., 2008</xref>
###xml 288 307 285 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib48">Robson et al., 2009</xref>
Although both activin-A and TGF-beta1 belong to the same family of cytokines, it would be unjust to have them considered as redundant during inflammatory processes, as also suggested by several studies (Ogawa et al., 2000; Werner and Alzheimer, 2006; Le et al., 2007; Ogawa et al., 2008; Robson et al., 2009). In fact, our experiments reveal that in vivo blockade of activin-A resulted in significant exacerbation of allergic airway disease despite the presence of endogenous TGF-beta1. Moreover, we demonstrate that activin-A and TGF-beta1 induce different regulatory T cell subsets, indicating that these two cytokines may also operate through distinct suppressive mechanisms. These findings suggest that, at least in our experimental settings, activin-A has a distinct (to TGF-beta1) role.
###end p 53
###begin p 54
Our findings introduce activin-A as a new member in the team of immune response regulation factors. Moreover, its implicit protective role in acute allergic airway disease places activin-A as a therapeutic target for allergic asthma. The role of activin-A in several facets of regulatory T cell biology, including generation, maintenance, and function, is of great importance and remains to be further elucidated. Finally, considering its suppressive effects on Th1-driven responses, an involvement of activin-A in the regulation of autoimmunity is highly probable and merits closer examination.
###end p 54
###begin title 55
MATERIALS AND METHODS
###end title 55
###begin title 56

###end title 56
###begin title 57
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice.
###end title 57
###begin p 58
###xml 20 23 20 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 15 23 15 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rag-1<sup>&#8722;/&#8722;</sup></italic>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
###xml 126 130 <span type="species:ncbi:10090">Mice</span>
BALB/c, BALB/c-Rag-1-/-, and OVA-specific T cell receptor transgenic DO11.10 mice were purchased from the Jackson Laboratory. Mice were housed at the Biomedical Research Foundation of the Academy of Athens's Animal Facility. Procedures were in accordance with the United States National Institutes of Health Statement of Compliance (Assurance) with Standards for Humane Care and Use of Laboratory Animals (no. A5736-01) and with the European Union Directive 86/609/EEC on the protection of animals used for experimental purposes.
###end p 58
###begin title 59
Experimental protocol of acute allergic airway inflammation.
###end title 59
###begin p 60
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
###xml 151 156 <span type="species:ncbi:10090">mouse</span>
###xml 203 207 <span type="species:ncbi:10090">mice</span>
###xml 283 287 <span type="species:ncbi:10090">mice</span>
###xml 417 421 <span type="species:ncbi:10090">mice</span>
###xml 498 503 <span type="species:ncbi:10090">mouse</span>
###xml 556 561 <span type="species:ncbi:10090">mouse</span>
###xml 627 631 <span type="species:ncbi:10090">mice</span>
###xml 714 718 <span type="species:ncbi:10090">mice</span>
###xml 757 762 <span type="species:ncbi:10090">mouse</span>
###xml 984 988 <span type="species:ncbi:10090">mice</span>
###xml 1011 1015 <span type="species:ncbi:10090">Mice</span>
Acute allergic airway inflammation was induced in mice using OVA in alum. In brief, BALB/c mice were sensitized with OVA at a concentration of 0.01 mg/mouse in 0.2 ml alum i.p. on days 0 and 12. Control mice received the same volume of PBS in alum (alum controls). Subsequently, all mice received three challenges with aerosolized OVA (5% for 20 min) via the airways between days 18 and 20. For blocking experiments, mice also received an affinity-purified polyclonal neutralizing antibody against mouse activin-A (R&D Systems) i.p. at a dose of 20 microg/mouse, 2-3 h before each OVA challenge. Other groups of OVA-challenged mice received similar doses of isotype control Ig (R&D Systems). In other experiments, mice received i.p. two doses (1.125 microg/mouse/day) of r-activin-A (R&D Systems) or PBS, 4-5 h before each OVA challenge. The optimal dose of r-activin-A was determined after titration experiments and was over endogenous activin-A levels in lungs and DLNs of allergic mice as measured by ELISA. Mice were euthanized 48 h after the final OVA challenge.
###end p 60
###begin title 61
AHR.
###end title 61
###begin p 62
###xml 277 297 277 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib70">Xanthou et al., 2007</xref>
###xml 20 24 <span type="species:ncbi:10090">mice</span>
AHR was measured in mice 24 h after the final OVA challenge (day 21) by whole-body plethysmography (Buxco Research Systems) to calculate enhanced pause (PenH). Responses to inhaled methacholine at concentrations of 3-100 mg/ml were measured for 1 min, as described previously (Xanthou et al., 2007).
###end p 62
###begin title 63
Analysis of BAL.
###end title 63
###begin p 64
###xml 54 74 54 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib70">Xanthou et al., 2007</xref>
BAL harvesting was performed as previously described (Xanthou et al., 2007). In brief, inflammatory cells were obtained by cannulation of the trachea and lavage of the airway lumen with PBS. Cytospin slides were prepared by Wright-Giemsa staining. All differential counts were performed blind and in a randomized order at the end of the study.
###end p 64
###begin title 65
Lung histology.
###end title 65
###begin p 66
###xml 138 158 134 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib70">Xanthou et al., 2007</xref>
###xml 810 815 <span type="species:ncbi:10090">mouse</span>
4-microm paraffin-embedded sections were stained with hematoxylin and eosin (H&E) to evaluate lung infiltration, as described previously (Xanthou et al., 2007). A semiquantitative scoring system was used to grade the size of lung infiltrates, whereby +5 signified a large (>3 cells-deep) widespread infiltrate around the majority of vessels and bronchioles, and +1 signifies a small number of inflammatory foci. Goblet cells were counted on periodic acid-Schiff (PAS)-stained lung sections using an arbitrary scoring system. In brief, PAS-stained goblet cells in airway epithelium were measured double blind using a numerical scoring system (0, <5%; 1, 5-25%; 2, 25-50%; 3, 50-75%; and 4, >75% goblet cells). The sum of the airway scores from each lung was divided by the number of airways examined (20-30 per mouse) and expressed as mucus score in arbitrary units.
###end p 66
###begin title 67
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human subjects.
###end title 67
###begin p 68
###xml 93 94 93 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 103 104 100 101 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 134 136 131 133 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">20</sub>
###xml 220 222 215 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1%</sub>
###xml 287 289 282 284 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">20</sub>
###xml 488 507 481 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib45">Phipps et al., 2004</xref>
###xml 509 533 502 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">Kariyawasam et al., 2007</xref>
###xml 667 669 660 662 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1%</sub>
###xml 722 724 715 717 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">20</sub>
15 individuals with atopic asthma with a 15% increase in forced expiratory volume in 1 s (FEV1) to beta2 agonist, or a methacholine PC20 of </=8 mg/ml were recruited. The median age was 25 yr (range = 19-46 yr), with FEV1% predicted to be 97% (range = 75.4-125.7%) with a methacholine PC20 of 2.1 mg/ml (range = 2-3.6 mg/ml; geometric mean +/- 95% confidence interval). All subjects demonstrated positive skin prick tests to aeroallergens (ALK). The study design is previously described (Phipps et al., 2004; Kariyawasam et al., 2007). Six healthy volunteers with no history of asthma or atopy with a median age of 30.5 yr (range = 27-42 yr), and with a predicted FEV1% of 100.4% (range = 80-104.3%) with a methacholine PC20 of >16 mg/ml were included. The study was approved by the Royal Brompton and Harefield Hospital Ethics Committee, and subjects gave written informed consent.
###end p 68
###begin title 69
Immunohistochemistry.
###end title 69
###begin p 70
###xml 166 184 166 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">Hamid et al., 1991</xref>
###xml 186 207 186 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib47">Robinson et al., 1993</xref>
###xml 404 422 394 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">Hamid et al., 1991</xref>
###xml 424 445 414 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib47">Robinson et al., 1993</xref>
###xml 1064 1084 1054 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">Franz&#233;n et al., 1993</xref>
###xml 1086 1108 1076 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib52">Rosendahl et al., 2001</xref>
###xml 1232 1256 1222 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">Kariyawasam et al., 2007</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 762 767 <span type="species:ncbi:9606">human</span>
###xml 852 856 <span type="species:ncbi:9925">goat</span>
###xml 874 879 <span type="species:ncbi:9606">human</span>
Human lung biopsies were collected in PBS, and transferred into 4% paraformaldehyde (Sigma-Aldrich) and then to 15% sucrose (Sigma-Aldrich), as previously described (Hamid et al., 1991; Robinson et al., 1993). Biopsies were embedded in Tissuetek OCT (Thermo Fisher Scientific), snap frozen, and stored at -80degreesC. 5-microm sections were cut and immunostaining was performed, as previously described (Hamid et al., 1991; Robinson et al., 1993). In brief, the alkaline phosphatase-antialkaline phosphatase method was used, and specific antibody binding was visualized using Vectastain ABC-AP kits and the Fast-Red chromogen (Vector Laboratories). All incubations were performed at room temperature. Washes were performed in PBS unless otherwise stated. Normal human serum (10%) was used to reduce nonspecific binding. An affinity-purified polyclonal goat antibody against human activin-A, and an irrelevant species IgG antibody (which served as negative control) were used (R&D Systems). Antibodies against activin-A receptors were made as previously described (Franzen et al., 1993; Rosendahl et al., 2001). Cell counts were performed in a blinded fashion using a microscope (model BH-2; Olympus Corp.), as previously described (Kariyawasam et al., 2007). The numbers of positively stained epithelial cells were counted along the entire basement membrane of each section using a squared eyepiece graticule (Olympus) and expressed as the percentage of positive cells. The numbers of positively stained infiltrating cells that were located below the basement membrane (submucosal cells) were determined by counting the whole section and expressed as cells per square millimeter.
###end p 70
###begin title 71
Cell culture, proliferation, and suppression assays.
###end title 71
###begin p 72
###xml 6 7 6 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 11 12 11 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 138 139 134 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 767 768 740 741 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 775 776 748 749 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 779 780 752 753 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 835 842 804 811 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 857 858 826 827 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1131 1132 1100 1101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1234 1235 1199 1200 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1279 1280 1244 1245 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 66 70 <span type="species:ncbi:10090">mice</span>
###xml 533 537 <span type="species:ncbi:10090">mice</span>
###xml 650 655 <span type="species:ncbi:10090">mouse</span>
###xml 685 690 <span type="species:ncbi:10090">mouse</span>
###xml 961 964 <span type="species:ncbi:31658">CFA</span>
###xml 974 979 <span type="species:ncbi:10090">mouse</span>
###xml 997 1000 <span type="species:ncbi:31658">CFA</span>
###xml 1029 1034 <span type="species:ncbi:10090">mouse</span>
###xml 1088 1092 <span type="species:ncbi:10090">mice</span>
5 x 104 CD4+ T cells were purified (Dynabeads) from LNs of BALB/c mice and stimulated for 48 h with 2 microg/ml of soluble anti-CD3 and 105 irradiated (3,000 rad) T cell-depleted syngeneic APCs in the presence of PBS or 50 ng/ml r-activin-A. Different concentrations of anti-CD3 antibody and r-activin-A were tested. In some experiments, neutralizing antibodies against IL-10R and TGF-beta1 (at 10 microg/ml; R&D Systems) or the respective Ig control were added. In others, 20 U/ml rIL-2 (PeproTech) was added. LN cells from DO11.10 mice were stimulated for 48 h with 125 microg/ml OVA in the presence of PBS, 50 ng/ml r-activin-A, 20 microg/ml anti-mouse activin-A, 20 microg/ml anti-mouse ALK4, or 20 microg/ml Ig control (R&D Systems). In other experiments, 5 x 104 KJ1-26+CD4+ T cells stimulated for 48 h with 0.25 microg/ml of OVA323-339 peptide and 105 irradiated APCs were used. For antigen-driven Th1 and Th2 responses, DLN cells were obtained from OVA/CFA (0.01 mg/mouse of OVA in 0.1 ml CFA) i.p. and OVA/alum (0.01 mg/mouse OVA in 0.2 ml alum), respectively, sensitized BALB/c mice and restimulated ex vivo with OVA. CD4+ T cell proliferation was measured after stimulation for 72 h. Cells were pulsed with 1 microCi/well [3H]thymidine for the final 12 h of culture. [3H]Thymidine incorporation was measured by a scintillation counter (Microbeta-Trilux; PerkinElmer).
###end p 72
###begin p 73
###xml 296 297 289 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 301 302 294 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 352 353 345 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 360 361 353 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 364 365 357 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 377 378 370 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 431 438 420 427 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
For in vitro suppression experiments, BALB/c mice were sensitized with OVA/alum and harvested DLN cells were stimulated ex vivo with 125 microg/ml OVA in the presence of PBS or 50 ng/ml r-activin-A or 2 ng/ml rTGF-beta1 for 4 d. Cultures were rested in medium containing 20 U/ml rIL-2 for 6 d. 105 CD4+ T cells were isolated and co-cultured with 5 x 104 KJ1-26+CD4+ T cells, 105 irradiated syngeneic APCs, and 0.25 microg/ml of OVA323-339 peptide. T cell proliferation was measured.
###end p 73
###begin title 74
Cytokine analysis.
###end title 74
###begin p 75
###xml 271 277 267 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6</xref>
Cytokines were measured in lung homogenates and culture supernatants using commercially available ELISA kits for IL-4, IL-10, IFN-gamma, IL-12 (OptEIA; BD), IL-13, activin-A, CCL11, CCL22 and CCL17 (R&D Systems), and IL-2 (Bender Medsystems). In experiments performed in Fig. 6, ELISA kits for IL-4 and IL-10 were obtained from R&D Systems.
###end p 75
###begin title 76
Adoptive transfer experiments.
###end title 76
###begin p 77
###xml 171 172 167 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 176 177 172 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 230 233 226 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 226 233 222 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rag1<sup>&#8722;/&#8722;</sup></italic>
###xml 49 53 <span type="species:ncbi:10090">mice</span>
###xml 186 191 <span type="species:ncbi:10090">mouse</span>
DLN cells from OVA/alum sensitized (i.p.) BALB/c mice were harvested and restimulated ex vivo with 125 microg/ml OVA and either PBS or 50 ng/ml r-activin-A for 4 d. 2 x 106 CD4+ T cells/mouse were transferred i.v. into BALB/c-Rag1-/- recipients. 36 h later, recipients were sensitized with OVA/alum and euthanized 10 d later. LN cells were restimulated ex vivo with OVA and proliferation was measured.
###end p 77
###begin p 78
###xml 6 7 6 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 11 12 11 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 144 145 144 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 152 153 152 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 156 157 156 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 189 192 189 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 185 192 185 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rag1<sup>&#8722;/&#8722;</sup></italic>
###xml 323 330 323 330 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 21 26 <span type="species:ncbi:10090">mouse</span>
###xml 166 171 <span type="species:ncbi:10090">mouse</span>
2 x 106 CD4+ T cells/mouse were obtained as described in the in vitro suppression experiments and adoptively transferred i.v., along with 2 x 106 KJ1-26+CD4+ T cells/mouse, into BALB/c-Rag1-/- recipients. 36 h later, recipients were sensitized with OVA/alum and euthanized 10 d later. DLN cells were stimulated with the OVA323-339 peptide and T cell responses were measured.
###end p 78
###begin p 79
###xml 28 29 28 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 33 34 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 43 48 <span type="species:ncbi:10090">mouse</span>
###xml 118 122 <span type="species:ncbi:10090">mice</span>
###xml 136 140 <span type="species:ncbi:10090">mice</span>
In other experiments, 4 x 106 CD4+ T cells/mouse, obtained as described, were adoptively transferred i.v. into BALB/c mice. 24 h later, mice were sensitized with OVA/alum, and 7 d later they received two challenges with aerosolized OVA (5% for 20 min).
###end p 79
###begin title 80
Determination of serum antibody concentration.
###end title 80
###begin p 81
###xml 100 120 100 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib70">Xanthou et al., 2007</xref>
###xml 192 196 <span type="species:ncbi:10090">mice</span>
OVA-specific IgE, IgG1, and IgG2a serum antibodies were measured by ELISA, as previously described (Xanthou et al., 2007). Hyperimmune serum from OVA-alum-sensitized and OVA-challenged BALB/c mice was used for the IgE, IgG1, and IgG2a standards.
###end p 81
###begin title 82
Flow-cytometric analysis.
###end title 82
###begin p 83
###xml 72 73 72 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 160 161 160 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 170 171 170 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 177 178 177 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 232 239 232 239 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 285 308 285 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">Fitzgerald et al., 2007</xref>
###xml 592 593 588 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 846 847 834 835 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 851 852 839 840 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 857 858 845 846 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 905 912 893 900 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 1023 1030 1011 1018 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 1108 1115 1096 1103 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 881 885 <span type="species:ncbi:10090">mice</span>
###xml 1062 1066 <span type="species:ncbi:10090">mice</span>
###xml 1178 1182 <span type="species:ncbi:10090">mice</span>
Cells were stained with antibodies to CD4, CD3, KJ1-26, CD25, CD11c, I-Ad, CD-86, IL-10 (BD), and T1/ST2 (MD Biosciences). For intracellular IL-10 staining, CD4+ T or CD4+KJ1-26+ T cells were stimulated for 24 h with anti-CD3 or OVA323-339 peptide and stained as previously described (Fitzgerald et al., 2007). In brief, cells were restimulated for 4 h with 10 ng/ml PMA (Sigma-Aldrich), 250 ng/ml ionomycin (Sigma-Aldrich), and 1 microl/ml GolgiStop (BD), followed by surface and intracellular staining according to the manufacturer's instructions (BD). For intracellular Foxp3 staining, CD4+ T cells were stimulated with 2 microg/ml anti-CD3, 2 microg/ml anti-CD28, and 20 U/ml rIL-2 for 3 d. Cells were washed and stained with conjugated antibodies to CD4, CD3, and Foxp3 according to the manufacturer's instructions (eBioscience). Sorted (CD4+CD25-CD62L+) T cells from DO11.10 mice stimulated with OVA323-339 peptide-loaded bone marrow-derived DCs were also used. In other experiments, DLN cells were harvested from OVA323-339 peptide/alum-immunized DO11.10 mice and restimulated ex vivo for 3 d with OVA323-339 peptide. In others, DLN cells from OVA/alum-sensitized BALB/c mice were stimulated ex vivo with OVA for 4 d and rested in rIL-2 for 6 d before FoxP3 staining. To perform the FACS analysis, we used a cytometer (Cytomics FC 500; Beckman Coulter). Cell death was determined by flow cytometry using annexin V/PI staining (BD).
###end p 83
###begin p 84
We are grateful to Dr. P. Verginis for critical reading of the manuscript and helpful discussions. We thank Dr. D. Simoes for help with the statistical analysis and lung function experiments, S. Spyridakis for assistance with flow cytometry, and A. Agapaki for histology preparations. We also thank Dr. S. Pagakis and J. Morianos for assistance with figure preparation.
###end p 84
###begin p 85
This work was supported by the Biomedical Research Foundation of the Academy of Athens (to V. Panoutsakopoulou and G. Xanthou); by a grant from the Hellenic Ministry of Development, General Secretariat of Research and Technology (03ED750 to V. Panoutsakopoulou); and by an unrestricted grant for research in respiratory medicine from GlaxoSmithKline (to G. Xanthou). C.M. Lloyd is supported by a Senior Fellowship from the Wellcome Trust (057704). D.S. Robinson is supported by a Wellcome Trust Research Leave Award for Clinical Academics. H.H. Kariyawasam is supported by an Imperial College Trust Fund. A.B. Kay is funded by the Imperial Trust.
###end p 85
###begin p 86
The authors have no conflicting financial interests.
###end p 86
###begin article-title 87
Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor beta.
###end article-title 87
###begin article-title 88
An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation.
###end article-title 88
###begin article-title 89
Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals.
###end article-title 89
###begin article-title 90
Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression.
###end article-title 90
###begin article-title 91
###xml 28 29 28 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 33 34 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 60 61 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.
###end article-title 91
###begin article-title 92
Cutting Edge: IL-2 is essential for TGF-beta-mediated induction of FoxP3+ T regulatory cells.
###end article-title 92
###begin article-title 93
###xml 65 69 <span type="species:ncbi:10090">mice</span>
Therapeutic potential of follistatin for colonic inflammation in mice.
###end article-title 93
###begin article-title 94
Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells.
###end article-title 94
###begin article-title 95
Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics.
###end article-title 95
###begin article-title 96
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.
###end article-title 96
###begin article-title 97
Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor.
###end article-title 97
###begin article-title 98
Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma.
###end article-title 98
###begin article-title 99
Follistatin is a candidate endogenous negative regulator of activin A in experimental allergic asthma.
###end article-title 99
###begin article-title 100
Antagonists of activin signalling: mechanisms and potential biological applications.
###end article-title 100
###begin article-title 101
Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma.
###end article-title 101
###begin article-title 102
Control of regulatory T cell development by the transcription factor Foxp3.
###end article-title 102
###begin article-title 103
Activin a promotes the TGF-beta-induced conversion of CD4+CD25- T cells into Foxp3+ induced regulatory T cells.
###end article-title 103
###begin article-title 104
Activin A: a novel player and inflammatory marker in inflammatory bowel disease?
###end article-title 104
###begin article-title 105
A critical role for eosinophils in allergic airways remodeling.
###end article-title 105
###begin article-title 106
Experimental allergic encephalomyelitis: neutralizing antibody to TGF beta 1 enhances the clinical severity of the disease.
###end article-title 106
###begin article-title 107
Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1.
###end article-title 107
###begin article-title 108
Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia.
###end article-title 108
###begin article-title 109
Activin A is an acute allergen-responsive cytokine and provides a link to TGF-beta-mediated airway remodeling in asthma.
###end article-title 109
###begin article-title 110
Remodelling and airway hyperresponsiveness but not cellular inflammation persist after allergen challenge in asthma.
###end article-title 110
###begin article-title 111
Basal expression of bone morphogenetic protein receptor is reduced in mild asthma.
###end article-title 111
###begin article-title 112
###xml 83 84 83 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 88 89 88 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent.
###end article-title 112
###begin article-title 113
###xml 80 84 <span type="species:ncbi:10090">mice</span>
Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice.
###end article-title 113
###begin article-title 114
Systemically (but not intrathecally) administered IL-10 attenuates pathophysiologic alterations in experimental pneumococcal meningitis.
###end article-title 114
###begin article-title 115
###xml 94 98 <span type="species:ncbi:10090">mice</span>
Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice.
###end article-title 115
###begin article-title 116
###xml 69 73 <span type="species:ncbi:10090">mice</span>
Inhibition of allergen-induced airway remodeling in Smad 3-deficient mice.
###end article-title 116
###begin article-title 117
###xml 31 35 <span type="species:ncbi:10090">mice</span>
Defining a link with asthma in mice congenitally deficient in eosinophils.
###end article-title 117
###begin article-title 118
T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation.
###end article-title 118
###begin article-title 119
###xml 107 113 <span type="species:ncbi:10090">murine</span>
Glia-dependent TGF-beta signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis.
###end article-title 119
###begin article-title 120
###xml 25 29 <span type="species:ncbi:10090">mice</span>
Different phenotypes for mice deficient in either activins or activin receptor type II.
###end article-title 120
###begin article-title 121
Functional analysis of activins during mammalian development.
###end article-title 121
###begin article-title 122
CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells.
###end article-title 122
###begin article-title 123
###xml 47 48 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 52 53 52 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor beta.
###end article-title 123
###begin article-title 124
T(H)1 cells control themselves by producing interleukin-10.
###end article-title 124
###begin article-title 125
###xml 84 89 <span type="species:ncbi:10090">mouse</span>
Activin A stimulates type IV collagenase (matrix metalloproteinase-2) production in mouse peritoneal macrophages.
###end article-title 125
###begin article-title 126
Activin A functions as a Th2 cytokine in the promotion of the alternative activation of macrophages.
###end article-title 126
###begin article-title 127
A dual role of activin A in regulating immunoglobulin production of B cells.
###end article-title 127
###begin article-title 128
Treg-mediated immunosuppression involves activation of the Notch-HES1 axis by membrane-bound TGF-beta.
###end article-title 128
###begin article-title 129
Activin A induces cell proliferation of fibroblast-like synoviocytes in rheumatoid arthritis.
###end article-title 129
###begin article-title 130
Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination.
###end article-title 130
###begin article-title 131
Acute allergen-induced airway remodelling in atopic asthma.
###end article-title 131
###begin article-title 132
Development in motion: helper T cells at work.
###end article-title 132
###begin article-title 133
###xml 165 173 <span type="species:ncbi:9606">patients</span>
Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma.
###end article-title 133
###begin article-title 134
Activin-A: a novel dendritic cell derived cytokine which potently attenuates CD40 ligand-specific cytokine and chemokine production.
###end article-title 134
###begin article-title 135
###xml 29 34 <span type="species:ncbi:9606">human</span>
Activin-A attenuates several human natural killer cell functions.
###end article-title 135
###begin article-title 136
###xml 66 72 <span type="species:ncbi:9606">humans</span>
Interleukin-10-secreting type 1 regulatory T cells in rodents and humans.
###end article-title 136
###begin article-title 137
Paradoxical effects of IL-10 in endotoxin-induced uveitis.
###end article-title 137
###begin article-title 138
Activation of the TGF-beta/activin-Smad2 pathway during allergic airway inflammation.
###end article-title 138
###begin article-title 139
Activation of bone morphogenetic protein/Smad signaling in bronchial epithelial cells during airway inflammation.
###end article-title 139
###begin article-title 140
Emerging challenges in regulatory T cell function and biology.
###end article-title 140
###begin article-title 141
Interleukin-17 is a negative regulator of established allergic asthma.
###end article-title 141
###begin article-title 142
The glycoprotein-hormones activin A and inhibin A interfere with dendritic cell maturation.
###end article-title 142
###begin article-title 143
###xml 5 12 <span type="species:ncbi:51239">vanilla</span>
From vanilla to 28 flavors: multiple varieties of T regulatory cells.
###end article-title 143
###begin article-title 144
A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage.
###end article-title 144
###begin article-title 145
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation.
###end article-title 145
###begin article-title 146
Chemical and biological characterization of the inhibin family of protein hormones.
###end article-title 146
###begin article-title 147
Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease.
###end article-title 147
###begin article-title 148
How regulatory T cells work.
###end article-title 148
###begin article-title 149
Mechanisms of suppression by supressor T cells.
###end article-title 149
###begin article-title 150
Interleukin 12p40 production by barrier epithelial cells during airway inflammation.
###end article-title 150
###begin article-title 151
###xml 78 83 <span type="species:ncbi:10090">mouse</span>
Inhibitory effect of activin A on activation of lipopolysaccharide-stimulated mouse macrophage RAW264.7 cells.
###end article-title 151
###begin article-title 152
Roles of activin in tissue repair, fibrosis, and inflammatory disease.
###end article-title 152
###begin article-title 153
Immunologic basis of antigen-induced airway hyperresponsiveness.
###end article-title 153
###begin article-title 154
###xml 96 111 <span type="species:ncbi:10090">transgenic mice</span>
Astroglial overproduction of TGF-beta 1 enhances inflammatory central nervous system disease in transgenic mice.
###end article-title 154
###begin article-title 155
Osteopontin has a crucial role in allergic airway disease through regulation of dendritic cell subsets.
###end article-title 155
###begin article-title 156
The biology of activin: recent advances in structure, regulation and function.
###end article-title 156
###begin article-title 157
Suppression of IL-6 biological activities by activin A and implications for inflammatory arthropathies.
###end article-title 157
###begin article-title 158
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease.
###end article-title 158
###begin article-title 159
###xml 74 79 <span type="species:ncbi:10090">mouse</span>
Activin A down-regulates the phagocytosis of lipopolysaccharide-activated mouse peritoneal macrophages in vitro and in vivo.
###end article-title 159
###begin p 160
###xml 240 241 240 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
Abbreviations used: Act-RIIA, activin receptor type IIA; AHR, airway hyperresponsiveness; ALK, activin-like kinase; alum, aluminum hydroxide; BAL, bronchoalveolar lavage; DLN, draining LN; EAE, experimental autoimmune encephalomyelitis; FEV1, forced expiratory volume in 1 s; Foxp3, forkhead box p3; H&E, hematoxylin and eosin; PAS, periodic acid-Schiff; PenH, enhanced pause; r-activin-A, recombinant activin-A.
###end p 160

